New York State Teachers Retirement System Lowers Holdings in IQVIA Holdings Inc. $IQV

New York State Teachers Retirement System lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 10.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 130,711 shares of the medical research company’s stock after selling 15,722 shares during the period. New York State Teachers Retirement System’s holdings in IQVIA were worth $24,827,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Artisan Partners Limited Partnership purchased a new position in shares of IQVIA in the second quarter worth $515,772,000. Norges Bank bought a new stake in IQVIA in the 2nd quarter valued at $270,160,000. AQR Capital Management LLC lifted its stake in IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after purchasing an additional 879,701 shares in the last quarter. Laurel Wealth Advisors LLC boosted its holdings in shares of IQVIA by 15,755.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock valued at $122,857,000 after purchasing an additional 774,681 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in shares of IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after purchasing an additional 606,391 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Down 0.6%

IQV stock opened at $240.94 on Tuesday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The firm’s 50-day moving average is $224.91 and its 200 day moving average is $201.35. The company has a market capitalization of $41.03 billion, a PE ratio of 33.05, a P/E/G ratio of 2.47 and a beta of 1.36. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same period in the prior year, the firm earned $2.84 EPS. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on IQV shares. Citigroup increased their price target on IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday, October 29th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. UBS Group boosted their price target on shares of IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research report on Thursday. JPMorgan Chase & Co. increased their price objective on shares of IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Finally, TD Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating and boosted their target price for the stock from $206.00 to $215.00 in a report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $249.19.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.